Category

In the news
Predicine Liquid Biopsy Outperforms Four other Leading ctDNA NGS Tests in a Study Led by Bristol Myers Squibb SILICON VALLEY, Calif., May 13, 2022 /PRNewswire/ — Predicine, Inc., a global molecular insights company, today announced the results of a new research study that demonstrated superior performance of the PredicineATLAS™ liquid biopsy next-generation sequencing (NGS) assay compared to four...
Predicine to Attend 2022 AACR Conference in New Orleans to Highlight the Launch of PredicineBEACON™, a Novel, Tissue-agnostic, Actionable Assay for Minimal Residual Disease (MRD) Detection and the Recent Publication of Several Studies in Genitourinary (GU) Cancers PredicineBEACON™ offers ultra-sensitive detection of disease recurrence and is compatible with blood, urine- and/or tissue specimens. Urine-based MRD has...
Predicine Expands Its Footprint in the Greater Chicago Area to Better Serve Their Patients by Increasing Daily Capacity and Faster Turnaround Time SCHAUMBURG, Ill., April 11, 2022 /PRNewswire/ — Predicine, a global molecular insights company committed to advancing precision medicine in oncology and infectious diseases, announces the grand opening of its Chicago lab in Schaumburg, IL on April 2, 2022. This lab...
Predicine to Present Six Studies, including the Demonstration of the Clinical Utility of Its PredicineBEACON™, a Tissue-agnostic MRD Liquid Biopsy Solution, in Genitourinary (GU) Cancers at 2022 ASCO-GU Annual Conference PredicineBEACON™ platform offers next-generation, tissue-agnostic MRD detection, leveraging blood, urine- and/or tissue-based comprehensive genomic profiling solutions in solid tumors including bladder, prostate, and renal tumors...
Predicine Appoints Clint Webb as New General Counsel to Support Its International Expansion SILICON VALLEY, Calif., Jan. 19, 2022 /PRNewswire/ — Predicine, a global molecular insights company, announced today that it has appointed Clint Webb as its new General Counsel (GC). This is the most recent of several executive appointments aimed at supporting Predicine’s international expansion and further developing its industry-leading liquid...
Predicine Appoints Dr. Dennis Merkle as New Chief Executive Officer SILICON VALLEY, Calif., Jan. 4, 2022 /PRNewswire/ — Predicine, a global molecular insights company, announced today that it has appointed Dennis Merkle, PhD, MBA, as its new Chief Executive Officer (CEO) for Predicine Europe as well as its Global Head of Biopharma Business. Dr. Merkle moves into the...
Predicine Appoints Linh H. Le as New Chief Financial Officer SILICON VALLEY, Calif., December 21, 2021 – Predicine Corporation, a global molecular insights company, announced today the appointment of Linh H. Le as its new Chief Financial Officer (CFO). Le brings decades of healthcare experience as a seasoned executive in medical device and clinical genetic...
Event October 22, 2021 Predicine CEO Dr. Shidong Jia will be presenting, along with academic and biopharma collaborators, on the liquid biopsy solutions provided by Predicine. Register for the Symposium (HERE)    
Predicine presented data highlighting the use of PredicineCARE and PredicineATLAS in patients with metastatic breast cancer and early stage bladder cancer. Publications can be found below: (Breast Cancer Abstract) (Bladder Cancer Abstract)    
Results from the study utilizing the PredicineCARE liquid biopsy assay evaluate the concordance of somatic alterations identified by standard tissue testing to those identified by analysis of urinary circulating tumor DNA in patients with urothelial bladder cancer. The publications can be found online at: (HERE)
1 2